@entity2151 reductase  M2 subunit expression and prognostic value in XXXX .

@entity1 @entity5 @entity189 @entity14 @entity2151 @entity16071
UNASSIGNED: The @entity2151 reductase  M2 subunit ( @entity16071 ) modulates the enzymatic activity of @entity2151 reductase, and is involved in @entity5 progression. Recently, high levels of @entity16071 expression were reported to correlate with poor survival outcomes in @entity1 with @entity14 . However, changes in @entity16071 expression in @entity189 ( @entity189 ), and its effect on the prognosis of this disease remain unknown. The aim of the present study was to analyze the expression of @entity16071 in @entity189 cell lines, and to identify whether @entity16071 may serve as a biomarker with which to assess the prognosis of @entity189 . The present study found that @entity16071 expression was higher in @entity189 cell lines and tissue samples than in noncancerous nasopharyngeal epithelial cell lines and noncancerous tissues, as shown by reverse transcription  -quantitative polymerase chain reaction analysis, western blotting and immunohistochemistry staining. Kaplan  -Meier survival analysis demonstrated that @entity1 with higher @entity16071 expression levels had poorer disease  -free survival outcomes than those with lower expression levels of @entity16071 . Univariate analysis showed that a lower survival rate was significantly associated with high @entity16071 expression levels [hazard ratio (HR),  6.424; 95%  confidence interval  (CI),  2.381  -17.333; P<0.001]. Multivariate analysis indicated that @entity16071 expression is an independent prognostic factor for @entity1 with @entity189 (HR, 3.461; 95 % CI, 1.204  -9.949; P=0.021). Overexpression of @entity16071 led to increased cell proliferation, colony formation, migration and invasion in  vivo. These results suggest that high levels of @entity16071 expression may be a useful predictor for survival in @entity1 with @entity189 and may serve as a novel prognostic indicator for these individuals.
